z-logo
Premium
MicroRNA Signature at the Time of Clinical HCV Recurrence Associates With Aggressive Fibrosis Progression Post‐Liver Transplantation
Author(s) -
Gehrau R. C.,
Mas V. R.,
Villamil F. G.,
Dumur C. I.,
Mehta N. K.,
Suh J. L.,
Maluf D. G.
Publication year - 2013
Publication title -
american journal of transplantation
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.89
H-Index - 188
eISSN - 1600-6143
pISSN - 1600-6135
DOI - 10.1111/ajt.12047
Subject(s) - medicine , microrna , cirrhosis , liver biopsy , fibrosis , hepatitis c , liver transplantation , hepatitis c virus , steatosis , transplantation , biopsy , fold change , gene signature , oncology , gastroenterology , immunology , virus , gene , gene expression , biology , biochemistry
Diagnosis and prediction of the severity of hepatitis C virus recurrence (HCV rec ) after liver transplantation (LT) remain a challenge. MicroRNAs have been recently recognized as potential disease biomarkers. Archival liver biopsy samples from 43 HCV+ LT recipients were collected at clinical HCV rec time and at 3 years post‐LT. Patients were classified as progressors (P = F0/F1) or nonprogressors (NP = F3/F4) according to the severity of fibrosis on the 3‐year biopsy. Training (n = 27) and validation (n = 16) sets were defined. RNA was isolated from all biopsies at clinical HCV rec time, labeled and hybridized to miRNA‐arrays. Progressors versus nonprogressors were compared using the two‐sample t ‐test. A p‐value ≤0.01 was considered significant. The ingenuity pathway analysis tool was used for microRNA and miRNA:mRNA ontology data integration. Nine microRNAs were differentially expressed between groups. A supervised cluster analysis separated samples in two well‐defined groups (progressors vs. nonprogressors). Pathway analysis associated those microRNAs with hepatitis, steatosis, fibrosis, cirrhosis and T cell‐related immune response. Data integration identified 17 genes from a previous genomic study as 9‐microRNAs signature targets. Seven microRNAs were successfully validated in the validation set using QPCR. We have identified a 9‐microRNA signature able to identify early post‐LT patients at high risk of severe HCV rec during long‐term follow‐up.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here